Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors

Jiang, Jing; Jin, Meishan; Suo, Jian; Wang, Yinping; He, Lina; Cao, Xueyuan

doi:10.3748/wjg.v18.i20.2569

Cited by 26 publications

(28 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, a few dogs received toceranib concurrent with NSAIDs alone, but the NSAIDs were reported to be prescribed for problems unrelated to their GIST (Table ). Although cyclooxygenase‐2 (COX‐2) is upregulated in humans with GISTs and some literature suggests an association with a malignant tumor phenotype, this relationship has not been definitively established . Whether humans with GISTs that express high COX‐2 activity have a worse outcome, or benefit from COX‐2 inhibition, are also unanswered questions .…”

Section: Discussionmentioning

confidence: 99%

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs

Berger

Johannes

Jergens

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundGastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive therapy for GISTs in dogs is sparse. High‐risk GISTs in humans respond to tyrosine kinase inhibition in the adjuvant setting.ObjectivesTo review cases of toceranib phosphate use in dogs with GISTs and provide initial assessment of possible biological activity. A secondary aim was to evaluate patient and tumor characteristics for possible prognostic value.AnimalsTwenty‐seven dogs with confirmed GISTs based on histopathology and immunohistochemistry treated with toceranib.MethodsRetrospective study in which cases of toceranib use in dogs with GIST were solicited using the American College of Veterinary Internal Medicine Oncology and Small Animal Internal Medicine listservs.ResultsFive of 7 dogs with gross disease experienced clinical benefit (71%; 3 complete responses, 1 partial response, 1 stable disease). These included 2 dogs with durable responses after toceranib discontinuation. Median progression‐free interval (PFI) in dogs with gross disease was 110 weeks (range, 36‐155 weeks). Median PFI in dogs with microscopic disease was 67 weeks (range, 9‐257 weeks). Metastasis at diagnosis (P = 0.04) and high mitotic index (P < 0.001) were associated with shorter PFI in toceranib‐treated dogs.Conclusions and Clinical ImportanceBiological activity of toceranib is evident in dogs with gross disease. Metastasis of GIST at diagnosis, as well as high tumor mitotic index, was associated with shorter PFI in toceranib‐treated dogs. Larger studies are needed to define postsurgical risk and refine the use of toceranib in dogs with gross and microscopic GIST.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs

Berger

Johannes

Jergens

et al. 2018

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…The prognostic roles of HER family members in GISTs are controversial. Some authors believe that detection of EGFR expression helps to precisely subdivide high‐risk GISTs for different prognoses, while others found no significant association between EGFR expression and prognostic analyses of GISTs . Recently, Wong et al .…”

Section: Discussionmentioning

confidence: 99%

“…Some authors believe that detection of EGFR expression helps to precisely subdivide high-risk GISTs for different prognoses, 13 while others found no significant association between EGFR expression and prognostic analyses of GISTs. 14,15 Recently, Wong et al 16 indicated that EGFR is unlikely to be useful as a screening immunomarker for wild-type GISTs. Nevertheless, all authors support the idea that GISTs could be potentially be candidates for anti-EGFR targeted therapy.…”

Section: Discussionmentioning

confidence: 99%

EGFR gene mutation in gastrointestinal stromal tumours

Shi

et al. 2017

Histopathology

View full text Add to dashboard Cite

show abstract

“…However, the Ki-67 proliferation index cannot be used to stratify GISTs in terms of risk of recurrence, as current classifications still rely on clinical and histomorphological parameters which do not include immunohistochemistrybased data. Some studies have suggested using Ki-67 immunostaining as an alternative to counting mitoses [22,32,33]. Fig.…”

Section: Methodological Considerationsmentioning

confidence: 99%

Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors

et al. 2015

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most common non-epithelial tumors in the digestive tract. Beyond surgery, therapeutic management depends on risk of recurrence. Risk evaluation of GIST takes into account location and size of the tumor, whether or not the tumor was intact or ruptured and mitotic index. The mitotic index lacks in intra- and interobserver reproducibility. In this study, we evaluated on 61 GISTs, the reproducibility of mitotic counting using classical hematoxylin-eosin-saffron (HES) staining, and its correlation with the mitotic count obtained through immunohistochemical staining for phospho-histone H3 (PHH3) and the proliferation index based upon Ki-67 immunostaining. Mitotic counts by HES and PHH3 staining and Ki-67 proliferation index were evaluated twice by three independent observers taking into account interpretation times per tumor for each technique. HES-based and PHH3-based mitotic counts and Ki-67 proliferation index correlated well and presented good intra- and interobserver reproducibility. PHH3 staining resulted in a slight but statistically significant difference of about two more mitotic figures per 5 mm(2) than the HES-based count, which might have put some borderline tumors in a different risk category. Immunohistochemical staining for PHH3 and Ki-67 allowed more rapid interpretation than mitotic counts based upon HES staining, but only PHH3 staining allows counting of mitoses. Immunostaining using anti-PHH3 and anti-Ki-67 antibodies will eventually provide improved recurrence risk stratification of GIST and may become effective ancillary tools in deciding on optimal therapeutic management.

show abstract

Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors

Abstract: Our results indicated that the expression of Ki-67 could be used as an independent prognostic factor for GIST patients.

Cited by 26 publications

References 26 publications

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs

Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs

EGFR gene mutation in gastrointestinal stromal tumours

Immunostaining of phospho-histone H3 and Ki-67 improves reproducibility of recurrence risk assessment of gastrointestinal stromal tumors

Contact Info

Product

Resources

About